Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becatecarin in Advanced Breast Cancer
NCT00005817Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of becatecarin in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 6 years and Toxicity Rates up to 6 years. Started Mar 2000; status: completed.
02
Drugs
becatecarin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005817.